Advertisement
U.S. Markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
126.67+1.57 (+1.25%)
At close: 04:00PM EST
126.76 +0.09 (+0.07%)
After hours: 05:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close125.10
Open125.76
Bid126.44 x 100
Ask126.79 x 100
Day's Range124.91 - 127.61
52 Week Range99.06 - 134.17
Volume851,927
Avg. Volume703,834
Market Cap7.658B
Beta (5Y Monthly)0.57
PE Ratio (TTM)17.94
EPS (TTM)7.06
Earnings DateNov 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est177.53
  • Zacks

    ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?

    ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • TipRanks

    Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler

    Piper Sandler lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $163 from $166 and keeps an Overweight rating on the shares. The firm notes Jazz shares are down about 30% since the closing of the GW acquisition in May 2021, even with Epidiolex-associated diversification and the success of Xywav. Though Piper is bullish on the transformative potential of the OX2R agonists in sleep/wake, it still envisions a sizable role for oxybate products, particularly in narcolepsy type 2 and i